Prolactin in men's health and disease. Review uri icon

Overview

MeSH

  • Biomarkers
  • Female
  • Humans
  • Male
  • Prognosis
  • Reproductive Health
  • Up-Regulation

MeSH Major

  • Hyperprolactinemia
  • Men's Health
  • Pituitary Neoplasms
  • Prolactin
  • Prolactinoma
  • Reproduction

abstract

  • To review physiology of prolactin (PRL), cause and managment of hyperprolactinemia, and discuss evolving diverse roles of PRL in men's health. Hyperprolactinemia can be physiologically found after sexual activities, exercise, lactation, during pregnancy, and after stressful venipuncture. Elevated PRL can be caused by medications use, renal failure, hypothyroidism, and by prolactinoma - PRL secreting tumors. Symptomatic hyperprolactinemia and prolactinomas should be treated to lower PRL levels, decrease tumor size, and restore gonadal function. Three modes of treatment are typically utilized: pharmacological, radiosurgery with gamma radiation, and external beam radiation. Pharmacological treatment of prolactinomas is mainly based on dopamine agonists. The most frequently used dopamine agonists are bromocriptine and cabergoline. Cabergoline becoming the preferred drug in the treatment of prolactinomas because of higher response rate and less side-effects. Bromocriptine has been recently approved to improve glycemic control in diabetes mellitus. PRL plays a diverse role in men's reproduction and health. Detecting and treating elevated PRL may not only improve infertility and hypogonadism but also have a positive effect on the metabolic profile of patient and control of glycemic control and metabolic profile - an important advantage considering dramatic and worldwide increase in obesity and diabetes.

publication date

  • November 2011

has subject area

  • Biomarkers
  • Female
  • Humans
  • Hyperprolactinemia
  • Male
  • Men's Health
  • Pituitary Neoplasms
  • Prognosis
  • Prolactin
  • Prolactinoma
  • Reproduction
  • Reproductive Health
  • Up-Regulation

Research

keywords

  • Journal Article
  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/MOU.0b013e32834bdf01

PubMed ID

  • 21941183

Additional Document Info

start page

  • 527

end page

  • 534

volume

  • 21

number

  • 6